Outlook Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $67.41M
- P/E (TTM)
- –
- Dividend yield
- –
About Outlook Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
The company is a biopharmaceutical business focused on developing and commercializing ophthalmic treatments for retinal conditions. Its lead product is ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab designed to treat wet age-related macular degeneration in adults as an alternative to off-label compounded bevacizumab. It also explores indications for diabetic macular edema and branch retinal vein occlusion, alongside maintaining rights to legacy biosimilar candidates. The company targets the global retina care community, serving patients, payors, and ophthalmologists or retina specialists.
The business commercializes ONS-5010/LYTENAVA directly in Germany and the United Kingdom, where it holds marketing authorization covering the European Union and European Economic Area member states. Manufacturing of the drug substance and finished vials occurs in the United States through third-party partners, and the company engages global distribution and launch partners across Europe and other international territories. The provided text does not state the location of the company's corporate headquarters.
Summary of the business section of Outlook Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Outlook Therapeutics, Inc.
- Headquarters
- Iselin, NJ
- Address
- 111 S. Wood Avenue, Unit #100 08830
- Phone
- (609) 619-3990
- Website
- outlooktherapeutics.com
- Employees
- 17, Sep 30, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- September 30
- Auditor
- KPMG LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- OTLK
- Exchange
- Nasdaq
- IPO date
- May 13, 2016
- Shares outstanding
- 243M, Aug 14, 2026
- Public float
- $26.90M, Mar 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Mar 14, 2024; 1-for-20 reverse, Mar 14, 2024; 1-for-8 reverse, Mar 18, 2019; 1-for-8 reverse, Mar 15, 2019
- SEC CIK
- 1649989
- CUSIP
- 69012T305
- ISIN
- US69012T3059
- LEI
- 5493007AWUJ6HPMCBH11
- EIN
- 38-3982704
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert Charles Jahr | Chief Executive Officer, Director | 151,515 |
| Lawrence A. Kenyon | Chief Financial Officer, Director | 106,956 |
| Kevin Michael Lundquist | Chief Financial Officer | – |
| Ventures & Investments GMS | Director | 22,092,068 |
| Ghiath M. Sukhtian | Director | 46,223,757 |
| Faisal Ghiath Sukhtian | Director | 220,972 |
| Yezan Munther Haddadin | Director | 66,167 |
| Kurt J. Hilzinger | Director | 423,655 |
| Randy H. Thurman | Director | 5,593 |
| Julian S. Gangolli | Director | – |
| Julia A. Haller | Director | – |
| Andong Huang | Director | – |
| Gerd Auffarth | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 CRussell Trenary III | $1.25M | -$2.99M | $1.16M | $4 | – |
| FY2025 Lawrence AKenyon | $476.17K | $400.64K | $1.16M | $4 | – |
| FY2025 Robert CJahr | $1.29M | $906.66K | $1.16M | $4 | – |
| FY2024 C. Russell Trenary III | $6.38M | $5.19M | $701.31K | $22 | – |
| FY2024 CRussell Trenary III | $6.38M | $5.19M | $701.31K | $22 | – |
| FY2024 Lawrence AKenyon | $0 | $0 | $701.31K | $22 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of September 30, 2025, we had 17 full-time employees, seven of whom were primarily engaged in research and development activities and commercialization of ONS-5010/LYTENAVA and five of whom have a Ph.D.”
Corporate history
Events identified from SEC filings